RAQUEL
RIVERA DÍAZ
Profesora asociada de Ciencias de la Salud
![Foto de Francisco José](/img/nophoto.png)
Francisco José
Gómez García
Publications dans lesquelles il/elle collabore avec Francisco José Gómez García (23)
2024
-
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363
2022
-
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406
-
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry
Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117
2020
-
Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760
-
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150
-
The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741
2019
2018
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800
-
Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016
Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 617-623
2017
-
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1700-1708
-
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 6, pp. 1021-1028
-
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321
-
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry
Actas dermo-sifiliograficas, Vol. 108, Núm. 1, pp. 52-58
-
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 108, Núm. 1, pp. 52-58
-
Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts
British Journal of Dermatology, Vol. 176, Núm. 3, pp. 643-649
2016
-
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209
-
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
Journal of the European Academy of Dermatology and Venereology, Vol. 30, Núm. 11, pp. 1942-1950
2015
-
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
Actas Dermo-Sifiliograficas, Vol. 106, Núm. 8, pp. 638-643
-
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
Actas dermo-sifiliograficas, Vol. 106, Núm. 8, pp. 638-643
-
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry
Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 1, pp. 156-163